PRMT5 heats up at AACR23

A growing wave of next-generation PRMT5 inhibitors is positioning itself for one of the largest precision medicine opportunities in cancer, with at least 12 companies presenting translational data at this year’s AACR.

PRMT5’s synthetic lethal relationship with MTAP — a metabolic enzyme deleted in about 15% of human cancers — gives the target the potential for a broad, tissue-agnostic market opportunity, attracting small and large companies alike. ...